ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Integrative and Regenerative Pharmacology
Anticoagulant-Free Preparation of Autologous Platelet-rich Plasma (PRP) / Fluid Platelet-Rich Fibrin (f-PRF): A Pre-Clinical Comparative Performance Study
Alice Assinger 1,2
Anita Pirabe 2
Jonas Santol 2
Muhammad Abbas 3
David Kuroki-Hasenöhrl 3
1. Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria, Vienna, Austria
2. Medizinische Universitat Wien Institut fur Gefassbiologie und Thromboseforschung, Vienna, Austria
3. Croma Pharma GmbH, Leobendorf, Austria
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Objective: This study aimed to validate and characterize the efficacy of a previously developed anticoagulant-free, single soft-spin centrifugation device for the preparation of autologous fluid-Platelet-Rich Fibrin (f-PRF). Introduction: f-PRF is generated via one-step soft-spin centrifugation of all blood to produce a platelet-enriched plasma for regenerative medicine use, without the need for additional chemical agents. This study validated the performance of a novel single soft-spin f-PRF preparation system. Methods: Sixteen healthy volunteers (94% female, ages 23-52) donated blood for a comparative analysis between ExprecellTM and Arthrex ACP® Double-Syringe systems. f-PRF was prepared using standardized centrifugation (420xg, 5 minutes) and characterized for cellular composition, platelet function, growth factors, and extracellular vesicles (EVs). Platelet activation was assessed via P-selectin expression and GPIIb/IIIa activation following stimulation using flow cytometry. Results: ExprecellTM yielded 20% more f-PRF volume (6.5-10.5 vs 5.5-9.0 mL) with excellent cellular depletion (>99% erythrocyte, >95% leukocyte reduction). Platelet counts and function were similar between systems, with preserved in vitro agonist responses in terms of P-selectin expression and GPIIb/IIIa activation. Most growth factors remained below detection limits, and those detectable showed no differences between the devices. EV profiles from different cell types were also comparable. Conclusions: These findings support the ExprecellTM single soft-spin methodology, demonstrating that anticoagulant-free f-PRF preparation achieves functional equivalence to conventional methods while providing a statistically significant increase in volume yield and procedural simplicity. The closed system design reduces contamination risk and Luer-lock compatibility facilitates integration into clinical workflows. Maintained in vitro biological activity supports clinical utility for this innovative point-of-care f-PRF preparation device. Future studies are needed to demonstrate the clinical benefit of the f-PRF obtained.
Summary
Keywords
fluid-platelet rich fibrin2, performance5, Platelet-rich plasma1, platelets3, rejuvenation4
Received
12 January 2026
Accepted
19 February 2026
Copyright
© 2026 Assinger, Pirabe, Santol, Abbas and Kuroki-Hasenöhrl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: David Kuroki-Hasenöhrl
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.